GANX Gain Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why GANX matters now
Gain Therapeutics, Inc. (GANX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.82 with +1.68% on the session and $77.6M in market capitalization; recent performance reads 1-month +18.24% and YTD -41.61%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.6M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.2%.
The latest indexable market news headline is "Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Fuggetta Gianluca filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.67
P/S
0.00
EV/EBITDA
-3.18
DCF Value
$0.61
FCF Yield
-24.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-201.4%
ROA
-113.3%
ROIC
-130.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.6M | $-0.13 |
| Q4 2025 | $0.00 | $-4.5M | $-0.11 |
| FY 2025 | $0.00 | $-20.2M | $-0.61 |
| Q3 2025 | $0.00 | $-5.3M | $-0.15 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.80
Target (Median)
$8.00
Target Range
$4.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.16
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.